ABCL-040: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent Bruton's Tyrosine Kinase Inhibitor in Previously Treated Mantle Cell Lymphoma and Other Non-Hodgkin Lymphomas: Phase 1/2 BRUIN Study Results - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Clinical Lymphoma, Myeloma & Leukemia Année : 2021

ABCL-040: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent Bruton's Tyrosine Kinase Inhibitor in Previously Treated Mantle Cell Lymphoma and Other Non-Hodgkin Lymphomas: Phase 1/2 BRUIN Study Results

Domaines

Cancer
Fichier non déposé

Dates et versions

inserm-03546766 , version 1 (28-01-2022)

Identifiants

Citer

Jonathon Cohen, Nirav Shah, Alvaro Alencar, James Gerson, Manish Patel, et al.. ABCL-040: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent Bruton's Tyrosine Kinase Inhibitor in Previously Treated Mantle Cell Lymphoma and Other Non-Hodgkin Lymphomas: Phase 1/2 BRUIN Study Results. Clinical Lymphoma, Myeloma & Leukemia, 2021, 21, pp.S378-S379. ⟨10.1016/S2152-2650(21)01863-2⟩. ⟨inserm-03546766⟩
67 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More